Zenas BioPharma (ZBIO) reported Monday that a phase 3 trial of obexelimab in immunoglobulin G4-related disease showed a 56% reduction in the risk of disease flare.

However, Amgen (AMGN) had won approval from the US Food and Drug Administration for Uplizna in the chronic fibro-inflammatory disease last year after linking the B-cell-depleting therapy to an 87% reduction in the risk of flares versus placebo in a 52-week study, according to a report from Fierce Biotech.

Shares of Zenas plunged 56% as intraday trading volume rose to over 4.6 million from a daily average of roughly 444,000.

Salarius Pharmaceuticals (SLRX) said late Friday it intends to appeal a delisting determination on or before Jan. 7 by requesting an appeal with a Nasdaq Hearings Panel. A request for an appeal will stay the suspension of the company's securities pending the panel's decision.

The company intends to present its plans to regain compliance with the minimum bid price requirement.

Shares dropped 18%, with intraday trading volume rising to over 1.1 million from a daily average of 1.8 million.

Jabil (JBL) reported Monday the acquisition of Hanley Energy Group, a provider of energy management systems for data centers, in an all-cash transaction valued at roughly $725 million.

The deal includes a potential for $58 million in additional payments based on achieving revenue targets, the company said.

Shares of Jabil were down 6.4%, with intraday trading volume jumping to over 1.0 million from a daily average of 1.2 million.

Price: 224.98, Change: -15.41, Percent Change: -6.41